| Name | Title | Contact Details |
|---|
Cecelia Health partners with health plans/providers seeking to improve quality measures, and pharmaceutical/medical device companies seeking to improve adherence.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Althea Technologies, Inc., based in San Diego, CA, is focused on reducing the time, risk, and overall cost of our partner's drug development efforts. We apply immediate resources, unsurpassed scientific expertise, and a vast knowledge of regulatory
Provides private mortgage insurance to residential mortgage lenders, including mortgage bankers, mortgage brokers, commercial banks, and savings institutions. (Nasdaq:TGIC).
SelectCare is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.